The PATI device from NeuroVice, designed to protect against oral injuries during seizures, is now available via BlinkRx, a prescription journey management platform. The partnership gives patients and caregivers access to direct ordering, transparent pricing, and home delivery, alongside personalized support throughout the prescription process.

Epilepsy affects roughly 65 million people worldwide, including 3.4 million in the United States, with about 45,000 children diagnosed each year. Around one in ten people will experience a seizure in their lifetime. Seizures can lead to preventable oral and soft-tissue injuries and complicate airway management, highlighting the need for safe, clinician-directed protective tools.

Dr. Ashlyn Sanders, founder and chief medical officer of NeuroVice, said: “Bringing PATI directly available to healthcare providers, caregivers, and patients is the culmination of years of work driven by personal experience. As someone who has experienced firsthand the fear and vulnerability that comes with having no safe option to protect against oral injury, I created PATI to empower patients and families with the tool they desperately need. We are proud to offer patients direct and frictionless access through BlinkRx.”

BlinkRx said the platform supports patients throughout the prescription journey, providing clear pricing, home delivery, and patient support. The platform also enables healthcare providers to streamline prescription fulfilment, while exploring payer coverage options to reduce out-of-pocket costs.

Manaw Mohan, senior vice president at BlinkRx, said: “We are proud to help NeuroVice bring an important prescription device to patients and their caregivers. Through BlinkRx, prescribers have a straightforward way to order PATI, patients get clear pricing and free delivery, and our team supports the process from prescription to fulfilment. And as payer coverage pathways develop, BlinkRx will explore plan coverage and automatically push eligible savings to patients.”

By improving accessibility to the PATI device, BlinkRx and NeuroVice aim to reduce the risk of seizure-related oral injuries and improve patient safety. The move also reflects growing interest in devices and digital tools that enhance clinical care while addressing practical barriers to therapy initiation and adherence.